JNJ

167.67

-0.1%↓

NVS

116.88

-0.19%↓

ABT

129.08

+1.35%↑

TMO

478.61

-1.23%↓

ISRG

499.76

+0.25%↑

JNJ

167.67

-0.1%↓

NVS

116.88

-0.19%↓

ABT

129.08

+1.35%↑

TMO

478.61

-1.23%↓

ISRG

499.76

+0.25%↑

JNJ

167.67

-0.1%↓

NVS

116.88

-0.19%↓

ABT

129.08

+1.35%↑

TMO

478.61

-1.23%↓

ISRG

499.76

+0.25%↑

JNJ

167.67

-0.1%↓

NVS

116.88

-0.19%↓

ABT

129.08

+1.35%↑

TMO

478.61

-1.23%↓

ISRG

499.76

+0.25%↑

JNJ

167.67

-0.1%↓

NVS

116.88

-0.19%↓

ABT

129.08

+1.35%↑

TMO

478.61

-1.23%↓

ISRG

499.76

+0.25%↑

Search

Lisata Therapeutics

Abierto

2.52 -2.7

Resumen

Variación precio

24h

Actual

Mínimo

2.35

Máximo

2.65

Métricas clave

By Trading Economics

Empleados

26

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+814.4% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-1.2M

18M

Apertura anterior

5.22

Cierre anterior

2.52

Lisata Therapeutics Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

29 jul 2025, 23:57 UTC

Adquisiciones, fusiones, absorciones

EQT: To Spend Y407.82B for Tender Offer

29 jul 2025, 23:56 UTC

Adquisiciones, fusiones, absorciones

EQT: Tender Offer Price Is Y5,700 a Share

29 jul 2025, 23:54 UTC

Adquisiciones, fusiones, absorciones

EQT To Start Tender Offer for Fujitec

29 jul 2025, 23:50 UTC

Charlas de Mercado

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 jul 2025, 23:36 UTC

Charlas de Mercado

Gold Steady Ahead of FOMC Decision -- Market Talk

29 jul 2025, 22:57 UTC

Charlas de Mercado

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 jul 2025, 22:50 UTC

Charlas de Mercado

Mondelez Warns of Price Increases in North America -- Market Talk

29 jul 2025, 22:44 UTC

Adquisiciones, fusiones, absorciones

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 jul 2025, 22:41 UTC

Adquisiciones, fusiones, absorciones

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 jul 2025, 22:41 UTC

Adquisiciones, fusiones, absorciones

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 jul 2025, 22:35 UTC

Ganancias

IGO Maintains Nova Life of Mine Production Guidance

29 jul 2025, 22:35 UTC

Ganancias

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 jul 2025, 22:35 UTC

Ganancias

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 jul 2025, 22:34 UTC

Ganancias

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 jul 2025, 22:34 UTC

Ganancias

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 jul 2025, 22:34 UTC

Charlas de Mercado
Ganancias

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 jul 2025, 22:33 UTC

Ganancias

IGO Had A$279.7 Million of Cash at End-June

29 jul 2025, 22:33 UTC

Ganancias

IGO 4Q Underlying Free Cash A$2.4 Million

29 jul 2025, 22:33 UTC

Ganancias

IGO FY Sales Revenue A$512.5 Million

29 jul 2025, 22:33 UTC

Ganancias

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 jul 2025, 22:32 UTC

Ganancias

IGO FY Nickel Production 17,173 Tons

29 jul 2025, 22:32 UTC

Ganancias

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 jul 2025, 22:32 UTC

Ganancias

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 jul 2025, 22:31 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

29 jul 2025, 22:31 UTC

Charlas de Mercado
Ganancias

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 jul 2025, 22:31 UTC

Ganancias

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 jul 2025, 22:31 UTC

Ganancias

IGO FY Spodumene Production 1.48 Million Tons

29 jul 2025, 22:30 UTC

Ganancias

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 jul 2025, 22:30 UTC

Ganancias

IGO 4Q Underlying Ebitda A$62 Million

29 jul 2025, 22:22 UTC

Ganancias

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Comparación entre iguales

Cambio de precio

Lisata Therapeutics Esperado

Precio Objetivo

By TipRanks

814.4% repunte

Estimación a 12 meses

Media 23.5 USD  814.4%

Máximo 32 USD

Mínimo 15 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Lisata Therapeutics Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

2

Comprar

0

Mantener

0

Vender

Finanzas

$

Acerca de Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.